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Abstract: Epithelial protein lost in neoplasm (EPLIN) has been implicated as a suppressor of cancer
progression. The current study explored EPLIN expression in clinical gastric cancer and its association
with chemotherapy resistance. EPLIN transcript expression, in conjunction with patient clinicopatho-
logical information and responsiveness to neoadjuvant chemotherapy (NAC), was explored in two
gastric cancer cohorts collected from the Beijing Cancer Hospital. Kaplan-Meier survival analysis
was undertaken to explore EPLIN association with patient survival. Reduced EPLIN expression was
associated with significant or near significant reductions of overall, disease-free, first progression or
post-progression survival in the larger host cohort and Kaplan Meier plotter datasets. In the larger
cohort EPLIN expression was significantly higher in the combined T1 + T2 gastric cancer group
compared to the T3 + T4 group and identified to be an independent prognostic factor of disease-free
survival and overall survival by multivariate analysis. In the smaller, NAC cohort, EPLIN expression
was found to be significantly lower in tumour tissues than in paratumour tissues. EPLIN expres-
sion was significantly associated with responsiveness to chemotherapy which contributes to overall
survival. Together, EPLIN appears to be a prognostic factor and may be associated with patient
sensitivity to NAC.
Keywords: EPLIN; gastric cancer; clinicopathology; prognosis; chemoresistance
1. Introduction
Gastric cancer is a common worldwide cancer which is diagnosed in excess of 1 million
people every year according to the International Agency for Research on Cancer (IARC)
GLOBOCAN project [1]. Despite its incidence and mortality decreasing over the past five
years, it remains the third most common cause of cancer death [1]. The main failures
of cancer treatment are local recurrence and metastasis. Additionally, the acquisition of
chemotherapy resistance is also a common reason contributing to treatment failure [2].
Recent systematic review and meta-analysis of the safety and efficacy of third and later line
therapy, following failure of initial therapy, in patients with advanced or metastatic gastric
or gastroesophageal cancer demonstrated their potential benefit and highlighted the need
for focused research on improving patient selection in order to identify those who could
benefit from such therapies [3]. Greater understanding of the mechanisms involved in
these processes is essential to improve patient management and treatments. For example,
studies focused on the role of claudin-18 in mouse models has highlighted that loss of
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claudin-18 can drive neoplastic development in the mouse stomach [4]. Research aimed at
identifying such drivers of progression or those involved in therapy response is vital in
aiding future patient management and treatment regimes.
Epithelial protein lost in neoplasm (EPLIN) is an actin binding cytoskeletal protein
involved in tumour progression, acting as a suppressor of cancer cell growth, invasion
and migration, and is frequently lost in numerous cancer types and cell lines [5–9]. EPLIN,
also known as LIMA1 (LIM domain and actin binding-1), was first discovered due to its
alterations between normal oral epithelial and human papilloma virus (HPV) immortalised
epithelial cells [10]. The EPLIN gene is located at chromosome 12q13.12 and has two
isoforms; a longer EPLIN-β and a shorter EPLIN-α isoform and has been found to be
expressed in various tissues [9,11,12]. EPLIN has been demonstrated to contribute to
stabilisation of the actin cytoskeleton and regulation of cell dynamics by interacting with
filamentous actin (F-actin), illustrating its crucial role in cell motility [13–15]. Additionally,
EPLIN engages in cell-cell adherence junctions by linking the cadherin-β-catenin-α-catenin-
EPLIN-F-actin complex. It is also suggested to interact with paxillin [11,16–18] and plays
an indispensable role in stabilising apical-basal polarity in epithelial cells [9]. Previous
studies revealed that EPLIN negatively correlates with epithelial mesenchymal transition
(EMT), invasiveness, metastasis, poor prognosis, mortality and therapeutic resistance in
human tumours such as prostate, breast, ovarian and oesophageal cancers [6,7,9,19,20], and
that epidermal growth factor (EGF) could cause protein phosphorylation and turnover of
EPLIN through an extracellular signal-regulated kinase (ERK) signal pathway to influence
EMT [21].
Collectively, EPLIN is known to contribute as a tumour/metastasis suppressor affecting
actin dynamics, cytoskeletal organisation, motility and cancer progression [9,20]. Loss of
EPLIN may account for dysregulation of cytoskeletal dynamics, alterations of cell motility
and cell-cell adhesion disruption which is believed to promote tumour proliferation, invasion
and migration [14,15]. Recently, scientific interest in EPLIN has grown, however its relevance
to gastric cancer remains unknown. In this study, we investigated the expression of EPLIN in
two gastric cancer cohorts to explore its correlation with clinicopathological factors and its
importance in responsiveness to neoadjuvant chemotherapy (NAC).
2. Materials and Methods
2.1. Gastric Cancer Tissue Collection
Two gastric cohorts were utilised in the current study. The first cohort contained
320 gastric cancer tissue samples and 175 paired normal background tissue samples, and
the second cohort contained 78 gastric cancer tissue samples and 80 normal background
tissue samples, available from a cohort comprising cancer and normal matched patient
tissues, and had additional patient information regarding patient responsiveness to NAC.
Both cohorts were obtained from the Beijing Cancer Hospital and have been previously
reported [22,23]. Tissue samples were immediately collected in labelled universal contain-
ers after surgery and stored in liquid nitrogen until used. The process was checked by a
consultant pathologist. This collection was supported by local ethics committee (Peking
University Cancer Hospital Research Ethics Committee, ethics number 2006021) with pa-
tients’ consent. Patients were routinely followed up and their clinical pathological details
were obtained. Clinical information of the patients and patients with NAC is outlined in
Tables 1 and 2, respectively.
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Table 1. Epithelial protein lost in neoplasm (EPLIN) log10 relative transcript expression in gastric cancer and normal tissues.
Characteristic Sample Number (n) Median TranscriptExpression Q1 Q3 p Value
Tissue Type
Tumour 320 3.848 2.457 4.919 0.7288 a
Normal 175 2.939 1.224 14.679
Gender 0.4147 a
Male 228 3.778 2.173 4.903
Female 92 4.155 2.611 5.092
T stage 0.121 b
T1 16 4.21 2.653 4.97
T2 26 4.589 3.114 5.357
T3 41 3.445 1.855 4.622
T4 229 3.847 2.07 4.911
0.0421 a
T1 + T2 42 4.356 3.079 5.155
T3 + T4 270 3.783 1.99 4.855
Nodal involvement 0.859 b
N0 70 4.154 2.059 5.054
N1 48 3.836 1.9 5.068
N2 65 3.847 2.44 5.005
N3 131 3.786 2.666 4.775
Metastasis status 0.9494 a
M0 278 3.9 2.327 4.909
M1 41 3.807 2.487 5.09
TNM stage 0.596 b
TNM1 25 4.352 2.983 5.047
TNM2 60 3.977 1.735 5.245
TNM3 217 3.786 2.487 4.798
TNM4 9 5.09 0.35 5.46
Borrmann classification 0.342 b
BorrmannII 9 4.231 -1.122 4.58
BorrmannIII 19 4.335 2.97 5.238
BorrmannIV 7 1.29 -0.93 5.18
0.364 a
BorrmannII + III 28 4.283 1.742 5.042
BorrmannIV 7 1.291 -0.933 5.178
Histopathologic type 0.45 b
Adenocarcinoma 236 3.976 2.668 4.913
Signet ring cell Carcinoma 5 4.235 1.768 5.146
Mixed 47 3.359 1.884 4.775
Differentiation 0.239 b
High 1 −6.666 - -
High-Mid 6 4.555 4.03 5.525
Mid 61 4.045 2.208 5.132
Mid-Low 81 4.147 2.734 4.826
Low 136 3.752 2.488 5.032
Survival status 0.3168 a
Alive 134 3.848 2.175 5.1
Death 183 3.807 2.455 4.739
0.387 b
Disease Free 119 3.847 2.666 5.131
Metastasis 15 4.032 1.723 4.906
Died of gastric cancer 183 3.807 2.455 4.739
Q1: first quartile; Q3: third quartile; a: Mann-Whitney U test; b: Kruskal-Wallis test.
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Table 2. EPLN log10 relative transcript expression in gastric cancer patients with neoadjuvant chemotherapy (NAC) and
paratumour tissues.
Characteristic Sample Number (n) Median TranscriptExpression Q1 Q3 p Value
Tissue Type
Tumour 78 1.135 0.325 1.816 <0.001 a
Paratumour 80 2.73 2.255 3.921
Gender 0.9867 a
Male 56 1.118 0.32 1.827
Female 22 1.16 0.334 1.816
Borrmann classification 0.258 b
BormannI 3 1.806 1.479 2.266
BormannII 12 1.676 1.125 1.898
BormannIII 31 1.162 0.15 1.923
BormannIV 7 1.038 0.958 1.109
0.071 a
BormannI + II 15 1.796 1.277 1.902
BormannIII + IV 38 1.04 0.5404 1.818
D2 Surgery status 0.9192 a
No D2 Surgery 21 1.212 0.473 1.809
D2 Surgery 57 1.109 0.152 1.83
Diameter length 0.5512 a
Diameter length > 50mm 36 0.976 0.152 1.74
Diameter length < 50mm 32 1.298 0.386 1.801
T stage 0.541 a
T1 + T2 7 1.877 −0.605 1.902
T3 + T4 70 1.092 0.325 1.796
Nodal involvement 0.0979 a
Node negative 12 1.707 1.195 1.946
Node positive 66 1.028 0.277 1.8
TNM stage 0.57 b
TNM1 3 1.877 −0.605 2.266
TNM2a 3 1.761 1.556 2.234
TNM2b 8 1.196 0.082 1.632
TNM3a 8 0.549 −0.505 1.793
TNM3b 11 0.903 −0.053 1.797
TNM3c 21 1.017 0.235 1.768
TNM4 23 1.438 0.348 1.875
0.113 a
TNM1 + 2a 6 1.819 1.016 2.242
TNM2b,3,4 71 1.042 0.3169 1.797
Recurrence status 0.269 a
No recurrence 53 1.318 0.473 1.881
Recurrence 24 0.93 0.064 1.781
Survival status 0.3935 a
Alive 26 1.334 0.451 1.879
Death 52 1.04 0.198 1.801
NAC response 0.3217 a
Response to NAC 26 1.504 0.486 1.906
No response to NAC 52 1.04 0.32 1.804
Q1: first quartile; Q3: third quartile; a: Mann-Whitney U test; b: Kruskal-Wallis test.
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2.2. Tissue Processing, RNA Extraction and cDNA Generation
Tissue samples were homogenised in TRI reagent (Sigma-Aldrich, Dorset, UK) us-
ing a handheld homogeniser (Cole Parmer, Cambridgeshire, UK) and RNA extraction
undertaken in accordance with the manufacturers’ guidelines. RNA concentrations were
standardised, to allow sample normalisation, and used as a template to generate cDNA
using a GoScript reverse transcription mix, Oligo (dT) kit (Promega, Southampton, UK) in
accordance with the manufacturers’ guidelines.
2.3. Real-Time Quantitative PCR (qPCR)
EPLIN transcript expression was quantified within the tissue cohorts using an
AmplifluorTM UniprimerTM Universal qPCR system (Intergen Inc., Oxford, UK). For-
ward and reverse primers, containing a Z sequence (5′-ACTGAACCTGACCGTACA-3′)
required for the incorporation of the FAM-tagged UniprimerTM probe and fluorescent
detection, were as follows; EPLIN forward AAGCAAAAATGAAAACGAAG and Z tagged
reverse ACTGAACCTGACCGTACAGACACCCACCTAGCAATAG. Each reaction con-
tained forward primer, reverse primer, tissue sample cDNA, UniprimerTM and 2× Preci-
sion FAST qPCR master mix (Primer Design, Eastleigh, UK) and was carried out using
a StepOnePlusTM Real-Time PCR System (Thermo Fisher Scientific, Leicestershire, UK)
under the following conditions: 95 ◦C for 10 min, 100 cycles of 95 ◦C for 10 sec, 55 ◦C for
35 sec and 72 ◦C for 10 sec. The transcripts were quantified alongside an internal standard,
containing known transcript copy numbers of a reference gene. Standard samples, serial
diluted from 108 to 101 concentrations were run alongside unknown samples on the same
plates, using the same reaction setup. From this a standard curve was generated and used
to subsequently determine relative transcript copy numbers of the unknown samples.
2.4. Kaplan-Meier Plotter Gastric Cancer Database
The association of EPLIN expression with survival outcomes was also analysed using
the publicly available Kaplan–Meier Plotter gastric cancer database [24]. The following
criteria were selected for the analysis. Affymetrix ID 217892_s_at was used to analyse
median survivals of first progression (FP), overall survival (OS) and post progression
survival (PPS) comparing high LIMA1 expression to low LIMA1 expression based on cut
off levels (median).
2.5. Statistical Analysis
Mann–Whitney U tests or Kruskal–Wallis tests were used to compare expression
between patient group and were undertaken using Minitab (version 14) (Minitab Ltd.,
Coventry, UK) and SigmaPlot (Version 11) (Systat Software Inc., San Jose, CA, USA)
statistical software. Kaplan-Meier survival analysis and Cox hazardous proportion analysis
were undertaken using the SPSS statistical software (version 11; SPSS, Chicago, IL, USA).
Box plots were prepared using GraphPad Prism software (version 8). A p < 0.05 was
regarded as statistically significant.
3. Results
3.1. Transcript Expression of EPLIN in Clinical Gastric Cancer and Association with
Clinicopathological Information
EPLIN expression within the first gastric cancer cohort was analysed according to gen-
der, the depth of primary tumour infiltration into the gastric wall (T category), nodal status,
metastasis status, TNM stage, Borrmann classification, histopathologic type, differentiation
and survival status (Table 1).
No significant difference in EPLIN transcript expression was found between gastric
tumour tissues and normal tissues (p = 0.7288) (Figure 1A). Interestingly, EPLIN expression
appeared to have a negative correlation with the depth of tumour infiltration into the
stomach wall and it was noted that the combined T1 + T2 group, combined to give a broader
overview and to combat low sample numbers in individual groups, had significantly
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higher levels of EPLIN transcript compared to the more invasive combined T3+T4 group
(p = 0.0421) (Figure 1B), though no-significant differences were observed between the
individual groups (Table 1). Additionally, the combined Borrmann II + Borrmann III group
displayed higher, though non-significantly, levels of EPLIN expression compared with
Borrmann IV group (Figure 1C) and no significant differences noted between individual
groups (Table 1). Furthermore, EPLIN transcript levels tended to be higher in the more
highly differentiated tissues compared to those with lower levels of differentiation, though
statistical significance was not reached (Figure 1D).
Figure 1. Association between EPLIN expression and T stage, Borrmann classification and differenti-
ation in gastric cancer. (A): No difference was noted in EPLIN expression between tumour tissues
and normal tissues. (B): The combined T1 + T2 group had significantly higher EPLIN expression than
combined T3 + T4 group. (C): The combined BorrmannII + BorrmannIII group had higher EPLIN
transcript expression compared to BorrmannIV group. (D): There was a decline in EPLIN expression
from high-middle differentiation to low differentiation. High differentiation group was not shown
because of low sample number. Shown as median log10 values with 95% cl. * p < 0.05.
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No significant difference was noted between EPLIN expression and gender, node
status, TNM stage, metastasis status, histopathologic type and survival status (Table 1).
3.2. Relationship Between EPLIN Expression and Overall Survival (OS) in Patients with
Gastric Cancer
We also compared EPLIN expression in conjunction with clinical outcomes. Data was
available for 307 patients followed up for 120 months. Patients were divided into high
EPLIN and low EPLIN expression groups, based on cut off level (median) and compared
to patient survival rates.
Patients with high EPLIN expression had a longer overall survival (median = 46.8
months, 95% cl: 28.893–64.707 months) compared to those with low EPLIN expression
(median = 29.9 months, 95% cl: 21.361–38.439 months) and this was found to be close to
statistically significant (p = 0.067) (Figure 2A). Moreover, multivariate analysis identified
EPLIN (p = 0.024), TNM stage (p < 0.001), T stage (p < 0.001), nodal involvement (p < 0.001),
metastasis status (p < 0.001), invasion (p < 0.001) and embolism (p < 0.001) as independent
prognostic factors for overall survival, with univariate analysis also identifying EPLIN as a
prognostic indicator of survival with close statistical significance (Table 3).
Figure 2. Relationship between EPLIN expression and clinical survival outcomes in gastric cancer
cohort. (A): Longer overall survival was seen in patients with higher EPLIN expression compared to
those with relatively lower EPLIN expression. (B): Patients with higher levels of EPLIN transcript
had a significantly longer disease-free survival than those with lower levels of EPLIN transcript.





Univariate analysis EPLIN 0.067 0.025
Multivariate analysis
TNM stage <0.001 <0.001
T stage <0.001 <0.001







3.3. Association of EPLIN Expression and Disease-Free Survival (DFS) in Patients with
Gastric Cancer
Similarly, EPLIN expression levels were compared to patient Disease-Free Survival
(DFS). Patients with high levels of EPLIN transcript displayed significantly improved
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DFS compared to those with low levels (high EPLIN expression median = 42.667 months,
95% cl: 27.170–58.183 months; low EPLIN expression median = 26.433 months, 95% cl:
17.466–35.401 months; p = 0.025) (Figure 2B). Furthermore, multivariate analysis found that
EPLIN (p = 0.015), TNM stage (p < 0.001), T stage (p < 0.001), nodal involvement (p < 0.001),
metastasis status (p < 0.001), invasion (p < 0.001) and embolism (p < 0.001) were seven
independent prognostic factors for DFS which was consistent with our EPLIN univariate
analysis (Table 3).
3.4. Association of EPLIN/LIMA1 Expression with Gastric Cancer Patient Survival in Publicly
Available Databases
We analysed the relationship between the expression of LIMA1 and the OS, FP and
PPS of gastric cancer patients. OS (n = 875), FP (n = 640) and PPS (n = 498) curves were
generated and obtained from the public online database, Kaplan-Meier plotter, which
includes gene expression and survival information of gastric cancer patients [24]. This
resource was used to explore LIMA1 (Affymetrix ID: 217892_s_at) expression and its
relation to gastric cancer patient survival rates.
Gastric cancer patients with high expression of LIMA1 had a significantly longer OS
than those with low expression of LIMA1 (HR = 0.67, 95% cl 0.57–0.8; p = 3.9 × 10−6)
(Figure 3A). Similarly, high expression levels of LIMA1 were also significantly associated
with increased FP time in gastric cancer patients (HR = 0.63, 95% cl 0.52–0.78; p = 8 × 10−6)
(Figure 3B). Significantly longer PPS was also observed in gastric cancer patients who
had high LIMA1 expression compared with those with relatively low LIMA1 expression
(HR = 0.65, 95% cl 0.52–0.81; p = 0.00011) (Figure 3C).
Figure 3. Analysis of LIMA1/EPLIN association with gastric cancer survival in online database.
(A): Patients with high LIMA1 expression had a significantly longer overall survival (OS) than those
with low LIMA1 expression. (B): Patients with high LIMA1 expression had a significantly longer
first progression (FP) survival time than those with low LIMA1 expression. (C): Patients with high
LIMA1 expression had a significantly prolonged PPS compared to those with low LIMA1 expression.
Images produced and obtained using Kaplan-Meier Plotter website [24].
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3.5. Implication of EPLIN Transcript Expression in Neoadjuvant Chemotherapy (NAC)
A second smaller cohort containing clinical information of gastric cancer patients
treated with NAC (n = 78) and normal tissues (n = 80) was utilised to explore the implica-
tions of EPLIN expression in patients with NAC, demonstrating the association between
EPLIN expression and the clinical pathologic features among these patients. Similar to
the previous cohort, the expression of EPLIN was analysed in conjunction with avail-
able clinicopathological information (Table 2). Interestingly, EPLIN transcript expression
was found to be associated with tumorigenesis in patients with NAC, with significant
reductions observed in tumour tissues compared with paratumour tissues (p < 0.001)
(Figure 4A). A downward trend in EPLIN transcript expression was observed from Bor-
rmannI to BorrmannIV but this was not statistically significant (Figure 4B). Combined
analysis, designed to give a broader overview and combat low sample numbers in such
groups and looking at EPLIN expression in BorrmannI + BorrmannII groups compared
to BorrmannIII + BorrmannIV groups demonstrated a generally higher level of EPLIN
expression in the combined BorrmannI + BorrmannII stage tumours compared to the com-
bined BorrmannIII + BorrmannIV stage tumours groups, with near significance observed
(p = 0.071). Additionally, tumours with diameter length >50mm had a non-significantly
lower EPLIN expression compared to that with diameter length <50mm (Figure 4C) and
elevated, though non-significantly, EPLIN expression was observed in the combined
T1 + T2 group compared to combined T3 + T4 group with deeper tumour invasion
(Figure 4D). Furthermore, EPLIN transcript levels were observed to be non-significantly
increased in patients who had no lymph node metastasis compared to those who had
lymph node metastasis (p = 0.0979) (Figure 4E). Similarly, increased EPLIN transcript
level was noted in earlier stage TNM1+2a tumour tissues than that with advanced stage
TNM2b+3+4, though this was not significant (Figure 4F). Moreover, patients accepting
NAC were divided into recurrence and no recurrence groups. EPLIN transcript levels
were found to be higher in the no recurrence group compared to those in recurrence group,
though this was not found to be statistically significant (Figure 4G). Additionally, EPLIN
expression in patients who were alive was higher than those who died but no significant
difference was observed (Figure 4H).
3.6. Relationship between EPLIN Transcript Expression and Prognosis in Patients with NAC and
Chemosensitivity
We next explored the potential implications between EPLIN transcript expression and
responsiveness to chemotherapy, comparing EPLIN transcript expression between groups
of patients who had or had not responded to NAC. A non-significantly higher level of
EPLIN transcript was observed in tumours responsive to NAC than those with no response
to NAC (Figure 4I).
To investigate the effect of EPLIN on the prognosis of gastric cancer patients with NAC,
76 patients with NAC were followed up for 100 months and OS and DFS analysed between
groups of patients with high or low EPLIN expression levels. Longer OS rates were seen
in patients with high EPLIN expression (median = 23.367 months; 95% cl: 8.199–38.535
months) compared to those with low EPLIN expression (median = 20.5 months; 95% cl:
14.306–26.694 months), but it did not reach statistical significance (Figure 5A). Patient DFS
was also examined to further explore the role of EPLIN in prognosis (Figure 5B). EPLIN
expression levels did not have any significant effects on disease free survival, though
interestingly, particularly in the initial stages, the lower EPLIN expression group appeared
to have better DFS rates.
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Figure 4. Correlation between EPLIN transcripts and clinicopathology information in gastric can-
cer with NAC. (A) EPLIN expression was significantly decreased in tumour tissues compared to
paratumour tissues. (B) A downward trend of EPLIN expression was observed from BorrmannI to
BorrmannIV. (C) Tumours with diameter length > 50 mm had a lower EPLIN expression compared
to that with diameter length < 50 mm group. (D): EPLIN expression was expressed at a higher
level in the combined T1 + T2 group compared to combined T3 + T4 group. (E): EPLIN expression
was increased in the node negative group compared to that in node positive group. (F): EPLIN
expression with earlier stage TNM1+2a was higher than those with advanced stage TNM2b+3+4.
(G): EPLIN expression was higher in no recurrence group compared to those in recurrence group.
(H): EPLIN expression in the alive survival group was increased compared to those in the death
group. (I): Higher levels of EPLIN expression was noted in tumours with response to NAC group
than those with no response to NAC group. Shown as median log10 values with 95% cl. ** p < 0.001.
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Figure 5. Relationship between EPLIN transcript expression and prognosis in patients with NAC and
chemoresistance. (A): Patients with NAC expressing higher EPLIN levels seemed to have a slightly
longer OS than those expressing lower EPLIN levels. (B): Patients with low EPLIN expression had
better rates of disease-free survival in the early time period than those with high EPLIN expression,
but in the later time period the rates of disease free in both groups were similar. (C): In patients
with low EPLIN expression, the overall survival distribution was undertaken based on the different
levels of responsiveness to NAC. (D): In patients with high EPLIN expression, the overall survival
distribution was conducted for the different levels of tumour response to NAC.
Regarding the EPLIN association with chemosensitivity, we plotted OS curves for
patients with different levels of responsiveness to NAC. In the patient group with low
EPLIN expression, the mean OS in tumours responsive to NAC was 36.39 months (95% cl:
20.941–51.839) and that in tumours with no response to NAC was 26.166 months (95% cl:
17.726–34.606 months) (Figure 5C). Similarly, OS in patients with high EPLIN expression
was also conducted based on levels of responsiveness to NAC. It was noted that the mean
OS in tumours responsive to NAC was 57.821 months (95% cl: 42.716–72.926 months)
and that in tumours with no response to NAC was 30.247 months (95% cl: 18.539–41.956
months) (Figure 5D). It was noted that the survival distribution for different levels of NAC
response in high EPLIN group was wider than that in the low EPLIN group (p = 0.004). It
suggested that EPLIN expression significantly influenced tumour responsiveness to NAC
which led to overall survival distribution.
4. Discussion
Gastric cancer is one of the most aggressive cancers in the world with a high mortality
rate. Despite improvements, gastric cancer still has poor prognosis due to low rates of early
diagnosis, limited treatments and tumour heterogeneity [25]. Recurrence, metastasis and
drug resistance are the main causes leading to treatment failure [2].
EPLIN is widely expressed in normal epithelial cells but frequently lost in cancer cells
and tissues [6–8,18,19].
However, the role of EPLIN in gastric cancer progression remains largely unknown.
Our present study explores the significance of EPLIN expression in clinical cohorts of
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gastric cancer, its usefulness as a prognostic factor and its potential relationship with
responsiveness to NAC. The initial, larger cohort of gastric cancer was analysed to assess
the association between EPLIN expression and clinicopathological details and prognosis,
with the second, smaller cohort containing patients receiving NAC, assessed to explore
the role of EPLIN in responsiveness to chemotherapy. There are some differences in the
observed correlations and trends between our two cohorts. In this study, we found gastric
cancer patients with low EPLIN expression were more likely to have cancer infiltration to
the gastric wall and reduced tumour differentiation. In addition, the present study assessed
the role of EPLIN in the prognosis of gastric cancer. Our study firstly established that high
transcript levels of EPLIN were notably associated with improved DFS in gastric cancer
and that increased EPLIN expression was also related to a long OS with near significance.
In the meantime, we used Kaplan–Meier Plotter database to analyse the prognostic value of
EPLIN in larger publicly available datasets, the outcome of which was consistent with our
present study and indicated a significant relationship in these larger cohorts. Multivariate
analysis also identified EPLIN as an independent prognostic factor of DFS and OS in
gastric cancer. However, EPLIN expression had no effect on T stage, node status, metastasis
status, TNM stage, Borrmann classification and histopathology. There are some limitations
about the relationship between EPLIN expression and clinicopathology and prognosis in
our research because of the limited number of cases in some subtypes which may limit
statistical significance. Collectively, the most significantly important observation in our
present study is the relationship between EPLIN and clinical outcome of gastric cancer
suggesting that EPLIN may serve as a positive prognosis factor and may also inhibit
tumour depth invasion and promote differentiation.
This clinical observation may be explained at the cellular and molecular level. Actin-
binding proteins are essential in regulating the dynamics of actin bundles and branched
actin filaments in epithelial cells which are involved in dynamic stabilisation, cell matrix ad-
hesion and cell migration [26]. EPLIN has been identified as an actin-binding protein with
EPLIN-α and EPLIN-β isoforms. Taha et al. suggested that EPLIN-α targeted to control
membrane protrusion dynamics while EPLIN-β aims to stabilise stress fibres [26]. Previous
studies demonstrated that EPLIN functions as a connection between the E-Cadherin-β-
Catenin-α-Catenin complex and actin filaments to maintain epithelial phenotypes, stabilise
actin cytoskeletal networks and maintain functional epithelial junctions [20]. EGF phospho-
rylates EPLIN which leads to EPLIN degradation via an ERK1/2 signalling pathway [9].
EPLIN phosphorylation or deletion may cause instability of the circumferential actin bun-
dle which weakens the cell-cell contacts resulting in loss of cell-cell adhesion and early
events of EMT [27]. EPLIN has also been demonstrated to modulate EMT via p53 [28]. In
keeping with this, EPLIN has been strongly linked to regulating the processes of cellular
invasion and motility [14,18,19,29]. Jiang et al. observed there was a correlation between
low EPLIN transcripts and clinical outcomes in breast cancer, with reduced EPLIN tran-
script expression observed in tumour compared to normal tissues, in grade 2 and grade 3
cancers compared to grade 1 cancer and in TNM4 stage tumours compared to TNM1 stage
tumours and low EPLIN transcript expression associated with poorer patient outlooks and
reduced overall and disease-free survival [7]. EPLINα overexpression in MDA-MB-231
cells could reduce tumour growth and migration [7]. In oesophageal cancer, the expression
of EPLIN was lower in aggressive tumours such as later TNM stage tumours, tumours
with deep infiltration, node-positive tumours and tumours with low levels of differentia-
tion. Enhanced EPLINα expression in the human oesophageal cancer cell line KYSE150
led to reduced cell invasion and decreased cell growth, but had no influence on cellular
motility [8]. EPLIN was also inversely associated with the aggressiveness and outcome of
ovarian cancer [19] and was similarly seen to be reduced in tumour compared to normal
pulmonary tissues, with reductions in EPLIN transcript levels observed in higher grade,
TNM stage and nodal involvement [30]. Similarly, Zhang et al. have further demonstrated,
utilising both global databases and immunohistochemical staining, that EPLIN expression
was reduced in metastatic prostate and colon tumours and in lymph node metastasis of
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prostate, colorectal, breast and squamous cell carcinoma of the head and neck (SCCHN)
cancer [6]. Taken together these previous observations are largely consistent with our
finding which implicated EPLIN as a protective factor in patients with gastric cancer.
The current study aimed to explore the relevance of EPLIN in relation to chemotherapy
responsiveness. Surgical resection is the main treatment for gastric cancer. However, many
gastric cancer patients are diagnosed at an advanced stage and surgery is not a suitable option.
NAC is the administration of therapeutic agents used before surgery. Its aim is to shrink the
size or extent of tumour for the purpose of possible removal, converting unresectable tumours
into resectable tumours and/or decreasing micro metastatic disease. It is usually used for
cancers which are too large to be removed easily and also can help indicate tumour sensitivity
to chemotherapy [31]. NAC can decrease tumour TNM stage, increase surgical resection rate
and decrease tumour related symptoms if successful [32]. NAC with docetaxel, oxaliplatin,
fluorouracil or capecitabine are usually used in clinic and the application of NAC in gastric
cancer therapy is important in order to improve survival rates [32].
Therefore, we further explored EPLIN expression in a smaller gastric cancer cohort
containing information related to patient response to NAC. Interestingly, in the group
with NAC, statistically lower EPLIN transcript expression was detected in tumour tissues
than in normal tissues. While, in our first cohort, there was no significant difference in
EPLIN expression between tumour tissues and normal tissues, though elevated levels were
observed in normal tissues. This might indicate that EPLIN played a more important role
in those larger tumours which required NAC. A lower EPLIN transcript level might lead
to an increased tumour size which results in a requirement of NAC in order to shrink the
tumour, so as to offer patients more surgical options.
Partially in keeping with this, lower EPLIN expression was seen in more aggressive
tumours, such as late TNM stages, lymph node metastasis, deep tumour invasion to gastric
wall, larger tumour size, and recurrence, though these lacked statistical significance. This
indication is partially in line with the observations of breast and oesophageal cancer cohorts
in our laboratory [7,8]. Survival analysis showed high EPLIN expression in gastric cancer
patients with NAC led to a better OS, though it was not found to be significant in this
smaller cohort, while EPLIN expression had little influence on DFS in patients with NAC.
Chemotherapy is a key therapy for gastric cancer, with NAC providing a possi-
ble treatment option for those with advanced disease. Nevertheless, one reason for
poor survival of gastric cancer patients is due to chemotherapy resistance [33–35]. Cur-
rently, there is only limited data regarding the influence of EPLIN in responsiveness to
chemotherapy. Zhang et al. demonstrated that EPLIN depletion significantly promoted cell
chemoresistance to the treatment of docetaxel and doxorubicin in ARCaPE prostate cancer
cells [6]. In the current study, the relationship between EPLIN and gastric cancer chemosen-
sitivity was investigated in patients with NAC. It was interesting to note that higher
EPLIN expression was observed in the NAC responsive compared to NAC non-responsive
tumours, though it did not reach significant impact in this relatively small cohort. We
also carried out OS distributions to further explore the influence of EPLIN expression on
responsiveness to NAC. This indicated that EPLIN is involved in chemotherapy sensitivity
which contributed to overall survival. Taken together, EPLIN may negatively regulate
the biological function of those gastric cancers which required NAC and might promote a
long overall survival. Additionally, EPLIN might contribute to tumour responsiveness to
chemotherapy, which might contribute to a better OS.
Together, the present study suggests that EPLIN might be a potential prognostic
indicator of gastric cancer and play a role in responsiveness to chemotherapy. Given the
high mortality rates attributed to metastasis and acquisition of therapy resistance, novel
investigations into the associated mechanisms and regulatory pathways involved in such
processes in gastric cancer are of key importance. Currently, EPLIN’s role in gastric cancer
remains relatively uncharacterised, though it has been highlighted in other cancers as
a metastasis suppressor with early implications in regulating therapy response. EPLIN
therefore represents an interesting avenue for further investigation in gastric cancer and
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holds potential as a novel marker or prognostic indicator and also as a novel candidate
potentially involved in therapy response. However, there are a number of limitations to our
current study and much remains unknown. For example, our analysis was undertaken in
relatively small cohorts, particularly so for the second cohort. Additionally, the observations
reported result only from the expression analysis of clinical sample and lack laboratory
investigation into gastric cancer cell model systems, both in vitro and in vivo. Finally, the
mechanisms related to any impact of EPLIN on such aspects in gastric cancer also remain
to be elucidated. Therefore, our initial findings require further studies and larger cohorts
to gain a better understanding of the role of EPLIN in gastric cancer, especially in its
involvement in chemoresistance and therapy response. Additional cell based and in vivo
work, combined with mechanistic analysis is now required to fully assess the role of EPLIN
in cell sensitivity to chemotherapeutics and to clarify its usefulness as a prognostic factor
or indicator of therapy response in gastric cancer patients. Undertaking such work will
provide novel opportunities for biomarker or therapeutic strategies related to EPLIN in
gastric cancer.
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